- OMass has entered into an exclusive collaboration & license deal with Genentech to develop & commercialize its preclinical oral small molecule program for inflammatory bowel disease
- As per the deal, OMass will receive $20M upfront & over $400M in preclinical, development, commercial, & sales milestones, with tiered royalties based on net sales
- Collaboration leverages OMass’ Odyssion platform to advance the small molecules for IBD, with OMass leading preclinical development to candidate selection & Genentech handling clinical development, regulatory activities, manufacturing, & commercialization
Ref: OMass Therapeutics| Image: OMass Therapeutics AND Genentech | Press Release
Related News:- Replicate Bioscience Collaborates with Novo Nordisk to Develop Novel srRNA Therapies for Cardiometabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
